reli
fluorescein
isothiocyan
dyelabel
cppptd
tend
lack
phenotyp
analysi
cargo
function
insid
cell
given
result
cours
bar
studi
use
fixat
techniqu
need
question
whether
prior
studi
may
bias
particular
combin
cppptd
hydrophob
dye
second
cell
given
popul
suscept
type
directuptak
mechan
contrast
cellular
uptak
cppptd
macropinocytosi
endocytosi
result
transduct
entir
popul
cell
essenti
amount
materi
present
insid
cell
suggest
unknown
epigenet
contribut
specif
phase
cell
cycl
defin
amount
metabol
cell
growth
final
evid
occur
vivo
preclin
model
human
clinic
trial
although
difficult
experi
design
control
ultim
tell
us
whether
cell
cultur
studi
directli
relat
molecul
transduc
cell
preclin
anim
model
well
clinic
trial
use
tat
cppptd
summari
studi
hiros
colleagu
bring
new
use
inform
cppptd
field
illustr
import
confirm
peptid
cargo
respons
observ
mechan
cellular
uptak
although
endocytosi
may
respons
vast
major
cppptd
intern
accumul
evid
suggest
direct
penetr
occur
threshold
concentr
conclus
influenc
cargo
must
consid
compar
endocytosi
direct
penetr
present
studi
highlight
could
explain
discrep
exist
within
field
cppptd
uptak
well
year
year
although
vaccin
avail
mani
viral
infect
readili
prevent
neutral
antibodi
vaccin
complex
pathogensinclud
virus
mutat
rapidli
may
requir
induct
broadli
crossreact
cellular
immun
responsesremain
elus
two
recent
articl
report
vaccin
vector
deriv
adenovirus
ad
three
differ
speci
isol
chimpanze
fece
vector
encod
antigen
express
cassett
place
delet
domain
found
highli
immunogen
mice
monkey
even
importantbecaus
mice
lie
monkey
exaggeratevector
express
region
hepat
c
viru
hcv
genotyp
induc
potent
sustain
transgen
productspecif
tcell
respons
human
volunt
tradit
vaccin
base
inactiv
attenu
pathogen
purifi
protein
modifi
toxin
cellular
immun
especi
tcell
respons
best
achiev
gene
transfer
vehicl
induc
de
novo
synthesi
vaccin
antigen
part
cleav
proteasom
cytoplasm
peptid
deriv
degrad
antigen
activ
transport
endoplasm
reticulum
associ
major
histocompat
class
antigen
undergo
transloc
cell
surfac
interact
tcell
receptor
cell
year
ago
replicationdefect
human
serotyp
adenoviru
vector
origin
develop
wwwmoleculartherapyorg
vol
april
american
societi
gene
cell
therapi
commentari
gene
therapist
correct
genet
defect
shown
potent
induc
b
cellmedi
immun
vector
far
immunogen
genet
vaccin
carrier
poxviru
plasmid
vector
also
induc
remark
sustain
immun
respons
like
vector
lowlevel
persist
transcript
activ
form
cell
nevertheless
alreadi
appreci
gene
therapist
confirm
vaccin
studi
preexist
neutral
antibodi
common
human
reduc
vector
transduct
rate
henc
express
transgen
product
year
ago
vector
deriv
chimpanze
ad
virus
sadv
adc
develop
circumv
preexist
neutral
antibodi
human
sinc
steadi
stream
public
shown
adc
vector
highli
immunogen
mice
nonhuman
primat
review
ref
recent
articl
colloca
et
al
therefor
highli
innov
confirm
wealth
previou
studi
never
theless
praiseworthi
breadth
isol
sequenc
excess
ad
virus
monkey
fece
clearli
ad
vector
use
vaccin
carrier
given
pathogen
induc
addit
desir
vaccin
antigenspecif
immun
respons
carrierspecif
neutral
antibodi
respons
render
vaccin
base
ad
viru
ineffici
subsequ
use
target
populationwheth
boost
induct
respons
pathogen
gener
new
simian
ad
vector
addit
alreadi
avail
thu
valu
howev
report
find
view
caution
rel
immunogen
vector
determin
use
gag
transgen
product
experi
limit
number
human
simian
serotyp
ad
vector
immunogen
individu
ad
vaccin
carrier
part
dictat
natur
transgen
well
characterist
express
cassett
presenc
intron
enhanc
may
explain
discrep
colloca
colleagu
result
earlier
studi
exampl
famili
member
famili
adenovirida
also
call
e
famili
member
previous
report
immunogen
mice
rhesu
macaqu
vector
rare
human
well
nonhuman
serotyp
ad
vector
origin
develop
overcom
preexist
neutral
antibodi
human
preval
rate
neutral
ize
antibodi
vari
depend
geograph
region
preval
rate
markedli
higher
human
resid
develop
countriesespeci
subsaharan
africathan
individu
unit
state
europ
addit
shown
anim
human
volunt
particip
illfat
step
trial
aim
test
efficaci
vector
prevent
chronic
infect
titer
adneutr
antibodi
respect
impact
perform
ad
vector
vaccin
colloca
et
al
test
seropreval
rate
caucasian
resid
unit
state
europ
report
frequenc
neutral
antibodi
differ
ad
virus
may
paint
unduli
optimist
pictur
true
valu
differ
adc
virus
vaccin
carrier
use
human
barn
et
al
describ
immunogen
express
hcv
phase
clinic
trial
vector
use
differ
dose
individu
primeboost
regimen
vector
induc
measur
tcell
respons
low
vector
dose
frequenc
vaccineinduc
cell
higher
upon
immun
respons
expect
anim
studi
domin
cell
produc
interferonalon
combin
tumor
necrosi
factor
show
broad
crossreact
differ
genotyp
hcv
remain
larg
activ
indic
sustain
level
granzym
limit
express
margin
vivo
expans
upon
booster
immun
heterolog
ad
vector
ad
vector
initi
hail
perfect
gene
deliveri
vehicl
correct
inherit
diseas
end
fail
achiev
sustain
gene
therapi
high
immunogen
subsequ
claim
fame
vaccin
deliveri
vehicl
call
question
aftermath
step
trial
studi
colloca
barn
colleagu
reconfirm
ad
vector
especi
human
lack
neutral
antibodi
continu
explor
vaccin
carrier
complex
pathogen
thwart
tradit
vaccin
